Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies

PURPOSE: Data from two noninferiority trials of a dexamethasone-sparing regimen were assessed for the impact of acute nausea and vomiting on delayed outcome in patients undergoing moderately emetogenic chemotherapy (MEC) or anthracycline plus cyclophosphamide (AC). METHODS: Chemo-naive patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Celio, Luigi, Bonizzoni, Erminio, De Braud, Filippo, Agustoni, Francesco, Aapro, Matti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729784/
https://www.ncbi.nlm.nih.gov/pubmed/26245497
http://dx.doi.org/10.1007/s00520-015-2871-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729784/
https://www.ncbi.nlm.nih.gov/pubmed/26245497
http://dx.doi.org/10.1007/s00520-015-2871-x

Ejemplares similares